EP1417976A1 — Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
Assigned to Santen Pharmaceutical Co Ltd · Expires 2004-05-12 · 22y expired
What this patent protects
According to the present invention, a novel pharmacological effect of a compound having a PI3 kinase inhibitory action was found. Study on a novel pharmacological effect of the compound having a PI3 kinase inhibitory action revealed that the compound has an action of reducing int…
USPTO Abstract
According to the present invention, a novel pharmacological effect of a compound having a PI3 kinase inhibitory action was found. Study on a novel pharmacological effect of the compound having a PI3 kinase inhibitory action revealed that the compound has an action of reducing intraocular pressure. Therefore, it is found that the compound having a PI3 kinase inhibitory action is useful as a therapeutic agent for glaucoma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.